Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Announces Endpoints Met in Phase 1b Gastric Cancer Immuno-oncology Trial

• Safety, tolerability & phase 2 dose determined

• Phase 2 trial first patient to be dosed early 2019

• 5 patients with partial responses

• 4 patients with stable disease

SYDNEY, Australia, 17 December 2018: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced meeting study endpoints and positive top-line results from the Phase 1b study of its HER-Vaxx gastric cancer vaccine in patients expressing the HER2 target protein.

The 14 patient study tested three dose levels of HER-Vaxx (10, 30 and 50 micrograms) in combination with current standard of care chemotherapy, cisplatin and fluorouracil or capecitabine. All dose levels showed an increased antibody response in patients.


For further information please download PDF attached:
Download this document